Alan M. Garber - 15 Apr 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: Director
Issuer ticker: VRTX
Reported as of: 15 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Apr 2026, 16:14:55 UTC
Prior SEC filing: 05 May 2025
Next SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Christiana Stevenson, Attorney-in-Fact

Key filing fact

Alan M. Garber filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 17 Apr 2026.

Key facts

This page summarizes Alan M. Garber's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Apr 2026, 16:14.

Change

Previous filing in this sequence was filed on 05 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001312907 Primary reporting owner

Garber Alan M

Relationship: Director
Address: C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Signature date: 17 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRTX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +34
Change %
Price: $442.50^*
Shares after: 34
Date: 15 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.